Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

NCT06654752 · View on ClinicalTrials.gov ↗

Study Summary

The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.

Conditions Studied

Interventions

  • OTHER Immediate Oral Antibiotics
  • OTHER Tailored Treatment: Oral Antibiotics only if Additional Treatment needed

Study Locations (20)

California

  • Children's Hospital of Los Angeles & Anton Yelchin Cystic Fibrosis Clinic — Los Angeles
  • Stanford University — Palo Alto
  • Rady Children's Hospital at University of California San Diego — San Diego

Minnesota

  • Children's Hospitals and Clinics of Minnesota — Minneapolis
  • The Minnesota Cystic Fibrosis Center & University of Minnesota — Minneapolis

Missouri

  • Children's Mercy Hospital — Kansas City
  • St. Louis Children's Hospital & Washington University School of Medicine — St Louis

Alabama

  • The Children's Hospital Alabama & University of Alabama at Birmingham — Birmingham

Arizona

  • Tucson Cystic Fibrosis Center — Tucson

Colorado

  • Children's Hospital of Colorado — Aurora

Georgia

  • Children's Healthcare of Atlanta & Emory University — Atlanta

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago & Northwestern University — Chicago

Trial Details

FieldValue
Enrollment Target 430 participants
Start Date 2024-12-01
Est. Completion 2029-02-28
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06654752

The ClinicalTrials.gov registry entry for NCT06654752 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, the Collaborative Health Studies Coordinating Center, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions — of which Immediate Oral Antibiotics is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06654752 reports 20 study locations spanning 16 distinct geographic areas — top geographies include California, Minnesota, Missouri. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06654752 about?

NCT06654752 is a clinical study titled "Streamlined Treatment of Pulmonary Exacerbations in Pediatrics". The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.

What is the current status of trial NCT06654752?

This trial is currently recruiting. It is a NA study. The enrollment target is 430 participants. The study started on 2024-12-01. Estimated completion is 2029-02-28.

What conditions does trial NCT06654752 study?

This clinical trial studies the following conditions: Cystic Fibrosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06654752?

The interventions under investigation include: Immediate Oral Antibiotics (OTHER), Tailored Treatment: Oral Antibiotics only if Additional Treatment needed (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06654752?

This trial is sponsored by University of Washington, the Collaborative Health Studies Coordinating Center, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06654752 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial